« Return to News | CROs/Service Providers

Quintiles Invests in Biotech

Friday, January 12, 2007 12:23 PM

Quintiles Transnational’s strategic partnering unit, NovaQuest, funded a total of $342 million in 16 investments into emerging biotech companies. Quintiles will also provide marketing expertise, strategic development and possibly product development and commercialization. The unit of NovaQuest charged with funding emerging biotech companies is called eBio.

C.G. 'Chip' Gillooly, NovaQuest’s global vice president of eBio. said there were three things that are currently driving the booming biotech sector today:

"First, biotech’s continued progress in developing promising new medicines.

Second, private capital markets continue to value these companies more favorably than the global public equities markets, thereby altering investor exit strategies.

Third, the value NovaQuest brings – the experience and intellectual capital necessary to advance experimental programs, non-dilutive financing, alternatives to premature out-licensing and access to Quintiles’ global development and commercialization resources."

Read the full press release here.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.